Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Applied Tumor Immunity

Prof. Dr. Dirk Jäger

The research group "Applied Tumor Immunity" with its close connection to the clinic is actively integrating clinical data with biomarker exploration and functional assays to understand and overcome T cell- and tumor-intrinsic mechanisms of resistance or escape mechanisms in immuno-oncology. Further, the host (gut) microbiome as a tumor extrinsic factor is a major determinant of response to immunotherapy and we will increase our focus on host-microbiome interaction. We are establishing methods to assess T cell fitness by T cell immunophenotyping and through this aim to define the phenotype of a successful T cell product for immunomonitoring of patients undergoing T cell therapy in the context of translational research programs.

In collaboration with the Department of Medical Oncology (UKHD), Prof. S. Eichmüller and Dr. R. Harbottle (DKFZ) and with strong support by the Dietmar-Hopp-Foundation we envision to establish a network in the area of immune and cellular therapies which integrates development, GMP production and administration. This will enable us to develop innovative therapy approaches and produce study drugs for Phase I trials at the NCT, the UKHD, for partner sites within the NCT network as well as to serve as manufacturer for approved cellular drugs.

to top
powered by webEdition CMS